OR WAIT null SECS
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Proprietary cell lines offer opportunities for achieving high AAV titers.
In the ATMP space, CGTs are hitting their stride with unprecedented approvals in the past year alone.
February 29, 2024
Webinar Date/Time: Thu, Mar 28, 2024 11:00 AM EDT
February 28, 2024
Nona Biosciences and Boostimmune will collaborate to develop ADCs against novel targets using Nona’s proprietary platform technology.
February 22, 2024
Daiichi Sankyo is investing approximately €1 billiion (US$1.08 billion) to expand its Pfaffenhofen an der Ilm, Germany, site for ADC development and production.
February 21, 2024
Webinar Date/Time: Wed, Mar 20, 2024 11:00 AM EDT
February 16, 2024
Webinar Date/Time: Thu, Mar 21, 2024 11:00 AM EDT
February 15, 2024
BioVaxys has acquired the full portfolio of discovery, preclinical, and clinical development-stage assets of the former IMV.
February 12, 2024
Under the new partnership, Samsung Biologics will develop and manufacture an antibody for a LegoChem Biosciences ADC candidate.
Webinar Date/Time: Tue, Mar 5, 2024 2:00 PM EST
February 09, 2024
The three non-commercial developers of ATMPs will benefit from enhanced support from the agency.
February 02, 2024